<div>India's Glenmark Pharmaceuticals' proposed generic version of Bayer AG's Finacea, a gel for treating the common skin condition rosacea, infringes Bayer's patent, a U.S. court ruled on Monday.</div><div> </div><div>The federal court in Wilmington, Delaware said Glenmark's proposed gel would be absorbed into the skin in a similar way to Finacea, violating Bayer's patent. Germany's Bayer had sued Glenmark in 2013 after Glenmark filed an application to market a copycat version of the $95 million drug in the United States.</div><div> </div><div>(Reuters)</div>
